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Dopamine is an inhibitory neurotransmitter involved in the pathology of schizophrenia.The
revised dopamine hypothesis states that dopamine abnormalities in the mesolimbic and
prefrontal brain regions exist in schizophrenia. However, recent research has indicated that
glutamate, GABA, acetylcholine, and serotonin alterations are also involved in the pathol-
ogy of schizophrenia. This review provides an in-depth analysis of dopamine in animal
models of schizophrenia and also focuses on dopamine and cognition. Furthermore, this
review provides not only an overview of dopamine receptors and the antipsychotic effects
of treatments targeting them but also an outline of dopamine and its interaction with other
neurochemical models of schizophrenia. The roles of dopamine in the evolution of the
human brain and human mental abilities, which are affected in schizophrenia patients, are
also discussed.
Keywords: dopamine, schizophrenia, cognition, glutamate, dopamine receptors, cannabis, animal models of
schizophrenia, evolution of the human brain
BRIEF HISTORY OF DOPAMINE HYPOTHESIS IN
SCHIZOPHRENIA
Dopamine, adrenaline, and noradrenaline are neurotransmitters
that belong to the catecholamine family. Dopamine is produced in
the substantia nigra and ventral tegmental regions of the brain, and
dopamine alterations are related to schizophrenia (1,2). Dopamin-
ergic projections are divided into the nigrostriatal, mesolimbic,
and mesocortical systems. Impairments in the dopamine system
result from dopamine dysfunctions in the substantia nigra, ventral
tegmental region, striatum, prefrontal cortex, and hippocampus
(3–5). The “original dopamine hypothesis” states that hyperac-
tive dopamine transmission results in schizophrenic symptoms.
This hypothesis was formed upon the discovery of dopamine
as a neurotransmitter in the brain by Arvid Carlsson (6–12).
Abbreviations: AMPA, (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)-
propionic acid; COMT, catechol-O-methyltransferase; CNS, central nervous
system; D (1), dopamine D1 receptor; D (2), dopamine D2 receptor; D (3),
dopamine D3 receptor; DAT, dopamine transporter; DAOA or G72, d-amino acid
oxidase activator; DLPFC, dorsolateral prefrontal cortex; GABA, γ-aminobutyric
acid; H-COMT, high-activity catechol-O-methyltransferase; L-COMT, low-activity
catechol-O-methyltransferase; Met, methionine; mRNA, messenger ribonucleic
acid; NMDA-receptor, N -methyl-d-aspartate receptor; PET, positron emission
tomography; PPI, prepulse inhibition; RNA, ribonucleic acid; SR, startle reflex; Val,
valine.
Dopamine receptor blockade by chlorpromazine and haloperidol,
proposed in 1963 by Arvid Carlsson and Margit Lindqvist, was a
cornerstone in psychiatry (13). However, the association between
schizophrenic symptoms and dopamine over-activity has already
been questioned (14). The positive symptoms of schizophrenia
include hallucinations and delusions as a result of increased sub-
cortical release of dopamine, which augments D2 receptor acti-
vation (15), and are thought to be due to a disturbed cortical
pathway through the nucleus accumbens (16). The negative symp-
toms of schizophrenia include anhedonia, lack of motivation, and
poverty of speech, which result from reduced D1 receptor acti-
vation (15) in the prefrontal cortex and decreased activity of the
nucleus caudatus (16). Alterations in D (3)-receptors might also
be involved in the negative symptoms of schizophrenia (17). Fur-
thermore, dopaminergic and serotonergic deviations are known
to contribute significantly to both the positive and negative symp-
toms of schizophrenia [review by Davis et al. (18); Castner and
Goldman-Rakic (19); Carlsson et al. (20)].
The “revised dopamine hypothesis” proposes hyperactive
dopamine transmission in the mesolimbic areas and hypoactive
dopamine transmission in the prefrontal cortex in schizophre-
nia patients (21–23). In addition to the mesolimbic brain areas,
dopamine dysregulation is also observed in brain regions includ-
ing the amygdala and prefrontal cortex, which are important
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for emotional processing (24). PET-studies (positron emission
tomography) have identified differences in dopamine contents in
the prefrontal cortex, cingulate cortex, and hippocampus between
schizophrenia patients and neuropsychiatric healthy control sub-
jects (25). In particular, the dopamine system in the hippocampus
is overactive in schizophrenia patients [review by Grace (26)].
RECENT ANIMAL MODELS IMPLICATING DOPAMINE IN
SCHIZOPHRENIA
The prepulse inhibition (PPI) of the acoustic SR (ASR) is a neuro-
physiologic measurement of sensorimotor gating and a marker for
information-processing deficits in neuropsychiatric disorders such
as schizophrenia (27–30). PPI refers to a reduced startle response to
a strong sensory stimulus when the stimulus is preceded by a barely
detectable stimulus (i.e., the prepulse). PPI is similar in human and
experimental animal models. Deficits in PPI can be produced in
rodents by administering psychotomimetics such as dopaminergic
and serotonergic agonists and glutamatergic antagonists (31–34).
Furthermore, dopaminergic stabilizers have been shown to restore
social behavior in a rat model of schizophrenia (35), and regula-
tory feedback loops exist among serotonergic, GABAergic, and
dopaminergic neurotransmitters (36). For example, interactions
between accumbal dopamine and various non-dopamine recep-
tors, such as N -methyl-d-aspartate (NMDA)-, AMPA-, GABA
(A)-, and nicotinic-receptors were reported in a rodent model
of schizophrenia (37). NMDA- and D (1)-receptors in the nucleus
accumbens interact with other, and this interaction is controlled
by PPI (38). GABA is also involved in the pathophysiology of PPI.
Pregnenolone, a neurosteroid in the central nervous system (CNS),
works by improving cognitive deficits through GABA, and preg-
nenolone improves PPI deficits in dopamine transporter knockout
mice (39). Activation of GABA-receptors in the rat brain results in
various receptor interactions with glutamate (40, 41), and modu-
lation of GABA (A) a5 receptors improves cognitive deficits in rats
(42). In a rat model of schizophrenia, the increase in dopamine is
caused by hyperactivity of the ventral hippocampus (43). Changes
in dopamine receptors (D-2) caused by antipsychotic drugs, such
as quinpirole, have been demonstrated in a validated rodent model
of schizophrenia (44, 45). However, recent work by Bay-Richter
et al. (46) indicates that antipsychotic drugs, such as AMP, cloza-
pine, and haloperidol, cause behavioral changes independent of
D (2)-receptors in a mouse model. An up-regulation of D2-high
receptors is a consistent feature in animal models of schizophre-
nia (47). However, alterations in D (3) dopamine receptors caused
by novel antipsychotic drugs, such as cariprazine, decrease cog-
nitive deficits in knockout mice (48). Therefore, D (3)-receptor
antagonists are recommended as a new pharmacological strategy
to improve cognitive function in schizophrenia [review by Naka-
jima et al. (49)]. Social isolation rearing in rats, which is a valid
neurodevelopmental model of schizophrenia, reduces dopamine
levels in the frontal cortex (50).
COGNITION IN SCHIZOPHRENIA
Cognitive deficits in schizophrenia affect working memory, lan-
guage and executive function, episodic memory, processing speed,
attention inhibition, and sensory processing (51). The prefrontal
region is affected in cognitive discrepancies connected with work-
ing memory [see the systematic review by Smieskova et al. (52)],
which consists of visual, verbal, central executive, episodic com-
ponents, and working memory disturbances in schizophrenia are
primarily due to altered dorsolateral prefrontal cortex (DLPFC)
function (51). Episodic memory discrepancies in schizophrenia
involve the medial temporal cortex, particularly the hippocam-
pus, and the prefrontal cortex, particularly the ventral and dor-
solateral prefrontal regions (51). Additionally, auditory process-
ing involving memory procedures is impaired in the working
memory of schizophrenia patients (53). Cognitive deficits cor-
relate with a decline in dopamine in the prefrontal cortex, pri-
marily at the level of D (1)-receptors (54–59) but also due an
imbalance of D (1) and D (2)-receptors in the prefrontal cor-
tex [review by Durstewitz and Seamans (60); Takahashi (61)].
Several studies have proposed that an inverted U-shaped rela-
tion between working memory and activation of the prefrontal
cortex exists in schizophrenia patients (62). There is ongoing dis-
cussion regarding the involvement of D (1)- and D (2)-receptors
in cognition in schizophrenia patients (63–66). Cognitive discrep-
ancies and working memory deficits in the prefrontal cortex are
associated with an increase in dopamine and D (1)-receptors in
the prefrontal cortex in schizophrenia patients (67, 68). Atypi-
cal antipsychotics such as clozapine block D (2)-receptors in the
striatum and 5-HT1A-receptors in the prefrontal cortex, which
results in increased dopamine activity (69, 70). By blocking D
(2)-receptors through antipsychotics, the apoptotic mechanisms
in the brain regions involved in cognition are impaired (71). The
disturbed activity of working memory in the DLPFC in schiz-
ophrenia patients is influenced by the release of dopamine in
the midbrain in schizophrenia patients, which is regulated by
a deficit in glutamatergic projection from the DLPFC to mid-
brain dopamine neurons (72). Extrastriatal dopamine transmis-
sion is necessary for attention and working memory, and these
deficits in the fronto–striato–thalamic pathway are involved in
cognition in schizophrenia (73). Newer antipsychotic drugs such
as olanzapine and clozapine, which have a better affinity for
dopamine receptors and blocking 5-HT2A receptors, decrease
the hyperactivity of the mesolimbic dopaminergic pathway and
improve the activity of D (1)-receptors in the prefrontal cortex
(74). Furthermore, nicotine improves cognition in schizophrenia
patients (75).
The COMT-Val-allele leads to a deficit in cognitive abilities.
Interactions between dopaminergic and methylation mechanisms
may result in cognitive deficits in schizophrenia patients. The
COMT Met-allele results in lower COMT-activity, leading to
greater production of dopamine and increased D (1)-receptor
activity in the prefrontal cortex and, subsequently, better cogni-
tive abilities in carriers of the Met-allele (76–82). A link between
Met-carriers and smoking has been recently reviewed (83), and
an association between COMT and cognitive dysfunction in bipo-
lar disorder has also been discussed (84). The COMT-alleles are
composed of two different alleles that result in varied activity lev-
els: the low-activity COMT-allele (L-COMT) and the high-activity
COMT-allele (H-COMT) (85). The L-COMT allele has the Met-
/Met-genotype, and the H-COMT allele has the Val-/Val-genotype
(86). Middle-aged healthy women with H-COMT who carry the
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Val158 allele show better cognitive abilities, including executive
processing and cognitive flexibility, than carriers of the Met allele
(87).
DOPAMINE RECEPTORS AND ANTIPSYCHOTIC EFFECTS IN
SCHIZOPHRENIA
Dopamine receptors are G-protein-coupled receptors and can be
divided into D (1), D (2), D (3), and D (4)-receptors (88). D
(1) receptors in the prefrontal cortex are decreased in schizophre-
nia patients and are unaffected by chronic treatment of typical
neuroleptics [review by Friedmann et al. (89)]. In contrast, D
(1)-receptors are increased in the parieto-temporal cortex in schiz-
ophrenia patients (90). Increased D2 mRNA has been found in
the frontal cortex in schizophrenia patients when compared with
neuropsychiatric healthy control subjects (91). Both the classic
and -current antipsychotic drugs act primarily by increasing high-
affinity D (2)-receptor expression (92–98). Haloperidol has been
shown to increase high-affinity D (2)-receptors in dopamine-
sensitive rats in an animal of schizophrenia (99). Dopamine ago-
nists bind to D (2)-high and D (2)-low-receptors (93, 100). This
D (2) two-state model is still controversial, although discussions
tend to doubt its validity, as demonstrated by in vitro binding
experiments (101). The action of dopamine agonists is related
to dopamine hyperactivity in psychosis (102). Dopamine antag-
onists and, to a lesser extent, dopamine agonists increase the D
(2)-high-receptors (103). This increase in D (2)-high-receptors
is a necessary basic requirement for the development of a psy-
chosis that correlates with dopamine supersensitivity (104). This
specific increase in D (2)-receptors and dopamine supersensi-
tivity might result in antipsychotic treatment failure (105, 106).
Although D (2)-receptor antagonists induce dopamine activity
(107), the mechanisms underlying the action of dopamine D (2)-
receptor antagonists are not entirely clear. The low therapeutic
advantage of dopamine D (2)-receptor antagonists and their high
pharmacological selectivity require future research (108). Antipsy-
chotic drugs block D (2) receptors and increase the release of
glutamate in the striatum (109), particularly on the right side of
the striatum, which is a brain region involved in cognition and
reward motivation (110). Glutamate agonists have an effect on
D (2) high-receptors in schizophrenia (111, 112). For example,
alterations in D (2)-receptor function caused by antipsychotic
medication in a rodent model of schizophrenia (44) or by the
application of an amphetamine in schizophrenia patients (113)
have been recently demonstrated. A D (2)-receptor occupancy
of 80% is considered essential for the positive effects of antipsy-
chotic medication (114, 115), whereas continuous high D (2)-
receptor occupancy is not required [review by Kapur and Seeman
(116); Remington and Kapur (117), systematic review by Uchida
et al. (118); Seeman (119)]. The atypical antipsychotic clozapine
results in a lower D (2) receptor occupancy than 80% but still
has positive effects [review by Nord and Farde (120)]. Schizo-
phrenia patients with extrapyramidal syndromes (EPSs) show an
increased D (2)-receptor occupancy (above 80%) in comparison
with schizophrenia patients with a good clinical response and no
EPSs (i.e., receptor occupancy of 65–80%) [review by Nord and
Farde (120)]. Lower doses of antipsychotics such as risperidone
are effective and do not induce EPSs (121, 122). This specific D
(2)-receptor occupancy in the striatum in schizophrenia patients
interacts with the antagonistic effects of 5-HT2A receptors [review
by Pani et al. (123)]. D (1)-receptors and NMDA-receptors coop-
erate with each other (124). Furthermore, the intensification of
D (2)-receptor antagonists by D (1)-receptor agonists results in
better NMDA transmission, exemplified by the action of clozap-
ine as a partial D (1)-receptor agonist (109). NMDA and D (1)
dopamine receptor interaction occurs through signal transduc-
tion and phosphorylation and dephosphorylation mechanisms
(125). D (1)-receptors are present in GABAergic interneurons
(54). For example, valproic acid affects GABA and, subsequently,
dopamine (126).
A slightly increased density of D (2)-receptors in basal condi-
tion and a significant increase in D (2)-receptors in the striatum
of schizophrenia patients has been found (127). This increase of
striatal dopamine D (2)-receptors in schizophrenia has also been
demonstrated in neuroimaging and molecular imaging studies
(128, 129). Specific neurotransmitter pathways such as those of
glutamate, GABA, and acetylcholine lead to a high-affinity of the D
(2)-receptor (130). Dopamine receptors such as the D (2)-receptor
contain receptor mosaics (i.e., RM; dimeric or high-order recep-
tor oligomers). These D2/NMDA receptor mosaics have also been
found in the ventral striato-pallidal GABA neurons. Decreased
D (2)-receptors in the thalamus and anterior cingulate cortex in
schizophrenia might suggest that they are involved in abnormali-
ties in dopamine transmission from the thalamus to the prefrontal
cortex (131).
Low doses of D (2)-receptor antagonists and signaling
enhancers of NMDA-receptors are recommended as new treat-
ments in schizophrenia [review by Fuxe et al. (132)]. In the asso-
ciative striatum, an increased D (2)-receptor availability has been
found in schizophrenia patients (127). Increased dopamine release
in the striatum is linked to substance dependence, such as amphet-
amine dependency, in schizophrenia (133). For example, stimula-
tion of NMDA/AMPA and kainate receptors by direct application
of glutamate or glutamate agonists increases the dopaminergic
cell-firing rate (133). However, the role of dopamine in the dys-
function of the striatum in schizophrenia patients requires future
research (134).
It can be summarized that, to date, the mechanism of
every effective antipsychotic medication in schizophrenia involves
dopamine and its interaction with other neurochemical pathways
such as those of glutamate, GABA, serotonin, and acetylcholine.
ALTERNATE NEUROCHEMICAL MODELS IN SCHIZOPHRENIA
AND THEIR INTERACTIONS WITH DOPAMINE
Deviations in dopamine and glutamate have been reported in
the prefrontal cortex of schizophrenia patients (135). NMDA-
receptors are involved in releasing dopamine into the striatum and
frontal cortex in schizophrenia patients [Ref. (136, 137), review
by Castner and Williams (138); Javitt (139); Balla et al. (140);
Laruelle (141)] and in rats in an animal model of schizophrenia
(142). These interactions are accompanied by calcium-dependent
changes (143) and exchanges between DAT and G72 in various
brain regions (144). In contrast to dopamine receptors, glutamate
receptors are found in the subcortical and cortical brain regions
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(145). The activity of dopamine is regulated by GABA and gluta-
mate. For example, corticostriatal glutamatergic pathways interact
with dopamine terminals (146, 147), and specific glutamate recep-
tors in the striatum, such as mGlu2, are sensitive to dopamine
(112). High glutamate levels have been found in the dorsal caudate
nucleus of schizophrenia patients (148). Adenosine interacts with
glutamate, NMDA-receptors, and dopamine [review by Burnstock
et al. (149)]. It can be summarized that NMDA-receptors and D
(1)-receptors in cortical brain areas such as the prefrontal cortex
and an excess of D (2)-receptors in subcortical brain areas such as
the striatum are interconnected with each other through a posi-
tive feedback mechanism (150). However, through its presynaptic
action, dopamine reduces the release of glutamate in the pyrami-
dal neurons of layer V in the prefrontal cortex (151). Dopamine
dysregulation in the basal ganglia of schizophrenia patients is an
important intrinsic feature in the pathology of schizophrenia and
not a medication side effect [review by Perez-Costas et al. (3)].
The finding by Brisch et al. (152) that astrocyte density is
increased in the frontal cortex in schizophrenia suggests a dis-
turbance in the dopamine–glutamate function. Furthermore,
Sokoloff et al. (153) demonstrated that D (3)-receptors either
act directly on NMDA-receptors at glutamate synapses on the
terminals of pyramidal cells in the nucleus accumbens or act
indirectly through dopamine at the presynaptic junction to reg-
ulate pyramidal cells in the prefrontal cortex. Indeed, injection
of NMDA-antagonists such as MK801 increases glutamate con-
centration in the frontal, retrosplenial, and cingulate cortices
(154). Glutamate dysfunction in the prefrontal cortex and hip-
pocampus causes the release of dopamine in the striatum (155).
A new focus on glutamatergic signaling mediated by NMDA
and metabotropic receptors may benefit new drug developments
[review by Field et al. (156); Javitt (139); Matosin and Newell
(157); Moghadam and Krystal (158); Noetzel et al. (159)]. The
review by Bernstein et al. (160) attributes the disturbed function
of astrocytes in schizophrenia to diminished glutamate metabo-
lism. The enzyme glutamine synthetase, which degrades glutamate
into glutamine, is located in glial cells and is decreased in schiz-
ophrenia patients (161). Additionally, the glutamate transporter
for astrocytes, GLT-1, is increased in schizophrenia patients (162).
Although Arai et al. (163) reported no association between glut-
amine synthetase and schizophrenia, the enzyme glutamine syn-
thetase displays gender-specific differences in schizophrenia (164)
and is involved in suicidal behavior (165,166). Moreover, the atypi-
cal antipsychotic agent risperidone increases glutamine synthetase
levels (167).
Through NMDA-stimulated GABA-release and GABAB-
receptor activity,glycine reduces the release of dopamine by modu-
lating DAT-type transporters in the prefrontal cortex and striatum
(168). The GABAB-receptor inhibits the release of glutamate in the
ventral tegmental area (169). A synergistic interaction of adeno-
sine and glutamate affecting the ventral striato-pallidal GABA
pathway has been demonstrated in a rat model (170). The inter-
actions of pyramidal neurons with dopamine receptors on their
dendrites and pyramidal cells with glutamate on their spines, and
GABAergic interneurons in the prefrontal cortex in schizophrenia
patients might offer new insights into receptor-targeted therapies
[Ref. (53); review by Wassef et al. (171); Lisman et al. (172)].
An increased number of GABA-cells expressing D (1)-receptors
exists in the rat prefrontal cortex (173). In the nucleus accumbens,
neurotensin (NT) inhibits dopamine discharge, which increases
glutamate release and activates the ventral striato-pallidal GABA
pathway, leading to a subsequent increase in glutamate transport
from the mediodorsal thalamus to the prefrontal cortex (174).
Another interaction between dopamine in the prefrontal cortex
and glutamate in the mediodorsal thalamus might be responsi-
ble for the effects of zotepine, which increases the extracellular
levels of noradrenaline, dopamine, glutamate, and GABA (175).
GABA interacts with acetylcholine by constraining its excitatory
contribution to cholinergic interneurons, which are decreased
in the striatum of schizophrenia patients, resulting in prefrontal
deviations in schizophrenia (176). Dopamine also interacts with
acetylcholine, which increases with smoking frequency in schizo-
phrenia patients (177). Acute nicotine administration might have
positive effects on cognition in schizophrenia patients [Ref. (178,
179), review by Mackowick et al. (180)].
Dopamine neurons in the midbrain release serotonin, which is
important during combined drug treatment with serotonin to pre-
vent the so-called serotonin syndrome, a surplus of serotonin in
some brain regions (181). Atypical antipsychotics involving sero-
tonin receptors include 5-HT1A receptor agonists or antagonists,
5-HT2A receptor antagonists, 5-HT2c receptor inverse or partial
agonists or neutral antagonists, 5-HT6 receptor antagonists, and
5-HT7 receptor antagonists (182).
Antipsychotics (such as clozapine and aripiprazole) possessing
5-HT-1A agonist properties induce hippocampal neurogenesis and
increase dopamine in the prefrontal cortex [review by Schreiber
and Newman-Tancredi (183)]. It can be summarized that vari-
ous serotonin–dopamine interactions, which include both direct
and indirect feedback mechanisms, contribute to the pathology of
schizophrenia [Ref. (151, 184–189), review by Arranz and de Leon
(190); Alex and Pehek (191); McCreary et al. (192); Bhattacharyya
et al. (193); Meltzer et al. (194); McMahon and Cunningham (195);
Gao et al. (196)].
Novel antipsychotic drugs, such as asenapine, increase
dopamine and glutamate levels in various subcortical and cor-
tical areas (197). New antipsychotic drugs with novel mechanisms
induce alterations in both dopamine and glutamate [review by
Paz et al. (198); Seeman et al. (99); Stone (199); Leroy et al.
(200); Coyle et al. (201)]. For example, metabotropic glutamate
and NMDA-receptors are future targets for new drugs (202,
203). A range of dopamine/serotonin, glutamate/serotonin, and
acetylcholine/serotonin interactions activate receptors and signal-
ing molecules in response to antipsychotic drugs and have been
observed in various brain regions, including the prefrontal cortex
and limbic regions, in schizophrenia (20, 98, 176, 182, 194, 204–
211). Future drug development should target signaling molecules
involved in dopamine, glutamate, and serotonin neurotransmis-
sion such as Akt and glycogen synthase kinase-3 (98, 212, 213) as
well as the control of presynaptic dopamine synthesis and release
(114). Stress in schizophrenia patients causes an increased release
of dopamine in the prefrontal cortex, which cannot be counter-
acted by reduced GABAA receptor complex activity, as well as
dendritic spine loss in the prefrontal cortex (214, 215). When used
in schizophrenic patients, cannabis induces hyperdopaminergic
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and hypoglutamatergic activities with both positive and nega-
tive symptoms (216). In particular, cannabis increases dopamine
transmission in the nucleus accumbens, which might cause or
aggravate psychoses (217). A high-low activity polymorphism in
COMT interacts with adolescent cannabis abuse, increasing the
risk for schizophrenia (218). Further, genes such as disrupted-in-
schizophrenia-1 (DISC1) play a role in stress pathways and the
metabolism of dopamine in schizophrenia [review by Hains and
Arnsten (219); Lipina et al. (220)].
DOPAMINE AND HUMAN EVOLUTION
The role of dopamine in human evolution has hitherto received lit-
tle theoretical attention. It is still unclear to what extent dopamin-
ergic expansion in hominin evolution was due to genetic adapta-
tions or epigenetic factors. Dopamine has expanded throughout
primate and hominin evolution and that dopamine is especially
concentrated in the prefrontal cortex, which is involved in higher
order functioning. The dopaminergic hypothesis contends that cli-
matic changes occurring in sub-Saharan Africa during the Pliocene
and Pleistocene periods, which resulted in increases of the Savan-
nah belt expanded hominin locomotory range. It is also speculated
that some human groups ventured to the more habitable African
southern coast leading to dietary changes (i.e., increasing amounts
of fish/shellfish) that aided dopaminergic expansion (221–223).
Dopamine increase may have also been linked with a concomitant
elevation in thyroid hormone production. Higher T4 found in
Homo may have represented an early endocrinological difference
between humans and other primates (224). In humans, T4 concen-
tration is associated with tyrosine conversion to dopa (a precursor
to dopamine); deficiencies of T4 concentrations are linked with
various neurological impairments (224).
Recent research suggests that from Homo erectus onward,
humans became persistence hunters, requiring various morpho-
logical and thermo-regulatory modifications (i.e., vascular reac-
tivity to temperature, large body surface area, plantar arch), which
provides approximately 20% energy return during running, elastic
tendons, short toes, more pronounced gluteus maximus muscle,
long legs, CNS coordination of metabolic, and cardio-vascular
responses to sustained running (225). From Homo erectus onward
there is an evident increase in stride size, which also optimized
ergonomic requirements of bipedalism while diminishing energy
requirements. Greater mass of slow twitch muscles would have also
assisted long distance locomotion. Long distance locomotion in
conjunction with greater hunting activities in ancestral hominins
incorporated all aspects of the CNS such as retention and memory
recall of large geographic areas, which maximized resource acqui-
sition. The locomotion/behavior interplay, which was mediated by
nerve cells and the dopaminergic system may have evolutionary
expanded cortical regions and neuro-hormonal organization in
ancestral hominins (225).
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